Trial Protocol ID USOR 22159_CELC-G-301_VIKTORIA-1

Trial Description

A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-Of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1)

Contact us regarding Clinical Trials at or call us at 877-664-7724


  • Jeanine L Werner, M.D.

Disease Types


  • Celcuity Inc. PSI-CRO NCT ID

  • NCT05501886